WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.
Ontology highlight
ABSTRACT: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. β-Catenin (CTNNB1)-mutated HCC represents 30% of cases of the disease with no precision therapeutics available. Using chemical libraries derived from clinical multi-kinase inhibitor (KI) scaffolds, we screened HCC organoids to identify WNTinib, a KI with exquisite selectivity in CTNNB1-mutated human and murine models, including patient samples. Multiomic and target engagement analyses, combined with rescue experiments and in vitro and in vivo efficacy studies, revealed that WNTinib is superior to clinical KIs and inhibits KIT/mitogen-activated protein kinase (MAPK) signaling at multiple nodes. Moreover, we demonstrate that reduced engagement on BRAF and p38α kinases by WNTinib relative to several multi-KI
SUBMITTER: Rialdi A
PROVIDER: S-EPMC10948969 | biostudies-literature | 2023 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA